Roche's cobas Epstein-Barr Virus Test Receives the US FDA's Authorization for Transplant Patients
Shots:
- The US FDA has granted de novo class II for cobas EBV test- providing HCPs a tool for monitoring transplant patients at risk for complications from infections or reactivations of EBV
- The cobas EBV test is a PCR viral load test that runs on the fully automated and widely available cobas 6800/8800 systems and has been calibrated to WHO’s international standard
- The test has received the FDA’s BDD and has robust coverage with a limit of detection of 18.8 IU/mL and an expanded linear range from 35 IU/mL-1E+08 IU/mL in EDTA plasma
Ref: Roche | Image: Roche
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com